Clinical trial · Observational
A Study of Metabolic Agents Following Brain Radiation
Pilot Imaging Study for CNS Metabolism
NCT06150547CI-TRIAL-00093509completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to determine if CEST magnetic resonance imaging (MRI) and FDG PET are feasible techniques to detect metabolic differences between tumor and brain in patients with a brain tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CNS Malignancy | Central Nervous System Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemical Exchange Saturation Transfer Magnetic Resonance Imaging | Diagnostic Test | — | UNRESOLVED |
| FDG Positron Emission Tomography | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Central Nervous System Malignant Tumor
- description
- Subjects may receive up to two CEST MRI's tests and/or up to two FDG PET. The physician will determine which test is appropriate based on your tumor type, past treatment history and research question. Tests will be completed at initial baseline visit and at least one other MRI/PET after the initial baseline, up to a maximum of four scans. Additionally, patients undergo finger-poke blood collection prior to receiving FDG on study.
- interventionNames
- Diagnostic Test: FDG Positron Emission Tomography
- Diagnostic Test: Chemical Exchange Saturation Transfer Magnetic Resonance Imaging
Primary outcomes (2)
- measure
- Number of subjects in whom glutamate metabolite is detected and measurable.
- timeFrame
- Baseline
- description
- Number of subjects in whom glutamate metabolite is detected and measurable via CEST MRI in tumor, brain, and/or the ventricular space.
- measure
- Number of subjects in whom n-acetylaspartate (NAA) metabolite is detected and measurable.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Radiographic evidence or histopathologic confirmation of CNS malignancy, with or without prior resection. * Provide written informed consent for the current study. * Willing to undergo at least one MRI (and possibly more at PI discretion) with proton and/or phosphorus magnetic resonance spectroscopy analysis. Exclusion Criteria: * Vulnerable populations: pregnant or nursing women (Arm B exempt), prisoners, mentally handicapped. * Cardiac pacemaker or artificial heart valve * Metal plate, pin, or other metallic implant * Intrauterine device, such as Copper-7 IUD * Insulin or other drug pump * Non-titanium aneurysm clips * Previous gunshot wound * Cochlear implant or other hearing device * Employment history as a metalworker (had metal in eye) * Permanent (tattoo) eye-liner * For FDG-PET specifically: Fasting blood sugar level greater than 200mg/dl
References
Publications (0)
Data not yet available
No reference posted for this study.